Sirolimus (SRL) is a promising drug for replacing calcineurin inhibitors. We performed this study to determine the optimal time of conversion from cyclosporine (CsA) to SRL in an experimental model of chronic CsA nephropathy. Three separate studies were performed. In the first study, SRL was given to rats with or without CsA for 4 weeks. In the second study, rats were treated initially with CsA for 1 week, and then switched to SRL (early conversion). In the third study, CsA was given for 4 weeks and then replaced by SRL for 4 weeks treatment of CsA (late conversion). The influence of SRL on CsA-induced renal injury was evaluated by assessing renal function, histopathology (interstitial inflammation and fibrosis), and apoptotic cell death. Combined CsA and SRL treatment significantly impaired renal function, increased apoptosis, and interstitial fibrosis and inflammation compared with CsA or SRL treatment alone. Early conversion to SRL did not change renal function, histopathology, or apoptosis compared with early CsA withdrawal. By contrast, late conversion to SRL significantly aggravated these parameters compared with late CsA withdrawal. In conclusion, early conversion from CsA to SRL is effective in preventing CsAinduced renal injury in a setting of CsA-induced renal injury.
INTRODUCTION
Sirolimus (SRL) is a promising maintenance immunosuppressive agent for replacing calcineurin inhibitors (CNI) (1) (2) (3) (4) . SRL itself does not cause severe nephrotoxicity, but combined SRL and CNI treatment causes significant nephrotoxicity in most animal and human studies (4) (5) (6) (7) (8) . There is an emerging consensus that conversion from a CNI to SRL is an effective strategy for reducing CNI-induced nephrotoxicity.
Clinical trials of SRL show that early conversion to SRL is effective in preserving graft function and that late conversion in recipients with poor graft function or proteinuria does not provide beneficial effects on graft function (9, 10) . Therefore, early conversion to SRL after transplantation is recommended, but the optimal time for conversion has not been determined. It is also unclear whether the undesirable effects of late conversion to SRL are related to the preexisting CNI-induced renal injury or to the effect of SRL itself.
In this study, we focused on the influence of SRL on Cyclosporine (CsA)-induced renal injury. To evaluate the optimal time for conversion, we compared the influence of early and late conversion from CsA to SRL on CsA-induced renal injury in an experimental model of chronic CsA-nephrotoxicity. The results of our study show clearly that early conversion from CsA to SRL is effective in preventing CsA-induced renal injury in an experimental setting of CsA-induced renal injury.
MATERIALS AND METHODS

Animals and drugs
The institutional animal care and use committee of the Catholic University of Korea approved the experimental protocol (CUMC-2008-0075-01), and all procedures performed in this study followed the ethical guidelines for animal studies. Male Sprague Dawley rats (Charles River Technology, Seoul, Korea), initially weighing 230 to 250 g, were housed in cages (Nalge Co., Rochester, NY, USA) in a controlled-temperature and controlled-light environment, and were allowed free access to a low salt diet (0.05% sodium, Teklad Premier, Madison, WI, USA) throughout the experimental period. After starting the treatment, the rats were pair-fed and daily body weight (BW) was monitored. Animals were anesthetized with ketamine. CsA (Novartis Pharma http://dx.doi.org/10.3346/jkms.2012.27.2.160
Ltd, Basel, Switzerland) was diluted in olive oil (Sigma Co., St Louis, MO, USA) to a final concentration of 15 mg/mL. SRL (Wyeth-Ayerst Research, Princeton, NJ, USA) was dissolved in solution of Tween 80 (10%), N, N-dimethylacetamide (20%), and polyethylene glycol 400 (70%), to a final concentration of 0.3 mg/mL.
Experimental design
Three separate experiments were performed, as shown Fig. 1 .
Experiment I:
This experiment was designed to evaluate the influence of the combined treatment of SRL and CsA on CsAinduced nephrotoxicity.
Rats were randomized to four groups and treated for 4 weeks. 1) Vehicle group (VH4, n = 7): rats received a daily subcutaneous injection of olive oil (1 mL/kg) for 4 weeks. 2) VH4 + SRL4 group (n = 7): rats received a daily subcutaneous injection of olive oil and SRL (0.3 mg/kg) for 4 weeks. 3) CsA4 group (n = 7): rats received a daily subcutaneous injection of CsA (15 mg/kg) for 4 weeks. 4) CsA4 + SRL4 group (n = 7): rats received a daily subcutaneous injection of CsA and SRL (0.3 mg/kg) for 4 weeks.
Experiment II:
This experiment was designed to evaluate the effect of early conversion from CsA to SLR on CsA-induced nephrotoxicity.
Rats were randomized to four groups and treated for 4 weeks.
1) VH1 + W3 group (n = 7): rats received olive oil for 1 week, after which olive oil was withheld for 3 weeks. 2) VH1 + SRL3 group (n = 7): rats received VH for 1 week and then SRL for 3 weeks. 3) CsA1 + W3 group (n = 7): rats received CsA for 1 week, after which CsA was withheld for 3 weeks. 4) CsA1 + SRL3 group (n = 7): rats received CsA for 1 week and then SRL for 3 weeks.
Experiment III: This experiment was designed to evaluate the effect of late conversion from CsA to SRL in established chronic CsA nephropathy.
Rats were randomized to four groups and treated for 4 or 8 weeks: 1) VH4 + W4 group (n = 7): rats received a daily subcutaneous injection of olive oil for 4 weeks, after which olive oil was withheld for 4 weeks. 2) VH4 + SRL4 group (n = 7): rats received a daily subcutaneous injection of olive oil for 4 weeks, and then SRL for 4 weeks. 3) CsA4 + W4 group (n = 7): rats received a daily subcutaneous injection of CsA for 4 weeks, after which the CsA was withheld for 4 weeks. 4) CsA4 + SRL4 group (n = 7): rats received a daily subcutaneous injection of CsA for 4 weeks, and then SRL for 4 weeks. The doses and duration of administration of the vehicle (Olive CsA4 + W4 (n = 7)
VH4 + SRL4 (n = 7)
CsA4 + SRL4 (n = 7) oil; 1 mL/kg), CsA (15 mg/kg), and SRL (0.3 mg/kg) were chosen based on previous reports (5, 11, 12) .
Measurement of renal function and whole blood CsA and SRL levels Serum creatinine (SCr) concentration was measured using a Cobas autoanalyzer (Roche Diagnotics, Division of HoffmanLa Roche Inc., Nutley, NJ, USA). Whole-blood CsA level was measured using a monoclonal radioimmunoassay (INSCTART Corp., Stillwater, MN, USA), and whole-blood SRL concentration was measured using a microparticle enzyme immunoassay (Abbott Diagnostics, Abbott Park, IL, USA).
Preservation of kidney
The kidneys were preserved by in vivo perfusion through the abdominal aorta. In brief, the animals were perfused with 0.01 M phosphate-buffered saline (PBS) to wash out the blood. The left kidney was removed for immunoblotting analysis or RNA extraction and the right kidney was removed after perfusion with the periodate-lysine-paraformaldehyde (PLP) solution for 4 min. The kidneys were removed and cut into sagittal slices of 1-2 mm thickness and post-fixed overnight in PLP solution at 4°C. A part of the PLP-fixed tissues was embedded in wax for trichrome staining. After dewaxing, 4-μm sections were processed and stained with Masson's trichrome stain.
Measurement of interstitial fibrosis
To assess interstitial fibrosis, kidney paraffin sections were stained with Masson's trichrome stain. Tubulointerstitial fibrosis (TIF) was identified using the definition described previously (13) . Briefly, a minimum of 20 fields per section was assessed using a color image analyzer (TDI Scope EyeTM Version 3.0 for Windows, Olympus, Tokyo, Japan). Randomly selected cortical fields of sections were analyzed histopathologically by two pathologists blinded to the identity of the treatment groups.
Immunohistochemistry of osteopontin (OPN) and ED-1
After dewaxing, sections were incubated with 0.5% Triton X 100/PBS solution and washed with PBS, and then incubated for 2 hr at 4°C in mouse antiserum against OPN (MPIIIB10, obtained from the Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA, USA) and ED-1 (Serotec Inc., Oxford, UK).
The number of ED-1-positive cells was quantified per 0.5 mm 2 area of rat kidney using a computer program (TDI Scope Eye Version 3.0 for Windows, Olympus). A minimum of 20 fields per section were assessed.
Immunoblotting of active caspase-3
Western blot analysis was performed as described previously (13) . Active caspase-3 was detected by incubating for 1 hr with a specific antibody (Chemicon International, Inc., MA, USA). Antibody-reactive protein was detected using enhanced chemiluminescence (ECL, Amersham Biosciences, Little Chalfont, UK). Optical density was measured using the VH group as 100% reference and normalized by β-actin.
Northern blot analysis of OPN
Northern blotting was performed as described previously by our laboratory (11) . The densitometric analysis was performed using the NIH ImagePC program for three determinations for each band, and the results were corrected to 18S.
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining
Cells undergoing apoptosis were identified by the ApopTag in situ apoptosis detection kit (Oncor Inc., Gaithersburg, MD, USA). The number of TUNEL-positive cells was counted in 20 different fields in each section under × 200 magnification (13, 14) .
Statistical analysis
The data are expressed as mean ± SEM. Multiple comparisons between groups were performed using one-way analysis of variance followed by Bonferroni post hoc testing (SPSS software version 9.0). Significance was assumed as P < 0.05.
RESULTS
Effect of combined treatment with SRL and CsA on chronic CsA nephropathy Table 1 shows the basic parameters for the first experimental group. After 4 weeks, the CsA group showed deterioration of renal function, as shown by an increase in SCr concentration com- pared with the VH4 and VH4 + SRL4 groups (P < 0.05). As expected, the combined CsA and SRL treatment significantly impaired renal function compared with the other groups (P < 0.05).
Kidney tissues from CsA-treated rats had typical striped interstitial fibrosis. Tissues from rats treated with combined CsA4 and SRL4 showed more interstitial fibrosis (39 ± 4/0.5 mm ) and CsA alone (24 ± 0.8/0.5 mm 2 ) (P < 0.01, Fig. 2 ). We used immunohistochemistry to stain for ED-1 to detect macrophage infiltration in this chronic CsA nephropathy model (13, 14) . As shown in Fig. 3A , ED-1-positive cells were observed rarely in the VH4 and VH4 + SRL4 groups. More ED-1-positive cells (68 ± 7/mm 2 ) were observed in kidneys from the CsA4 group than from the VH4 group (14 ± 2/mm 2 ), and VH4 + SRL4 group (15 ± 1/mm 2 ) (P < 0.01). The highest number of ED-1-positive cells was observed in the CsA4 + SRL4 group compared with CsA4 group (89 ± 5/mm 2 , P < 0.05). We used Northern blot analysis to measure the mRNA expression for OPN, a proinflammatory cytokine in animal models of CsA-induced renal injury (15, 16) . OPN mRNA was expressed minimally in the kidneys of the VH4 and VH4 + SRL4 groups. The expression of OPN mRNA was significantly higher in the CsA4 group (1,987% ± 179%) than in the VH4 group (100% ± 0.4%) and VH4 + SRL4 group (103% ± 3%) (P < 0.01 for the CsA4 group compared with other two groups). OPN mRNA expression was much higher in the CsA4 + SRL4 group (3,315% ± 361%) than in the VH4, VH4 + SRL4 (P < 0.01), and CsA4 groups (P < 0.05, Fig. 3D ). OPN protein expression followed a similar pattern (Fig. 3C) .
We used TUNEL staining and active caspase-3 expression for evaluation of apoptotic cell death, one of the mechanisms involved in the injury and repair process in the chronic CsA nephrotoxicity model (17) . Treatment with VH or SRL did not affect TUNEL-positive cells, which were observed rarely in the VH4 and VH4 + SRL4 groups (11 ± 0.7/0.5 mm 2 and 12 ± 0.5/0.5 mm 2 , respectively). However, the number of TUNEL-positive cells was higher in the CsA4 group (54 ± 2/0.5 mm 2 , P < 0.01 vs VH4 or VH4 + SRL4 groups), and even higher in the CsA4 + SRL4 group. (84 ± 2/0.5 mm 2 , P < 0.01 vs VH4 or VH4 + SRL4; P < 0.05 vs CsA4, Fig. 4A, B) , Immunoblotting analysis of the kidney showed a significant increase in active caspase-3 in the CsA4 group (3,541% ± 473%) compared with the VH4 (103% ± 11%) and VH4 + SRL4 group (105% ± 9%) (P < 0.01 for the CsA4 group compared with the other two groups). The expression of active caspase-3 was upregulated more in the CsA4 + SRL4 group (5,625% ± 473%) than in the CsA4 group (P < 0.05, Fig. 4C ). Table 2 shows the effect of early conversion from CsA to SRL on CsA-induced renal injury. Renal function did not differ between CsA early withdrawal (CsA1 + W3 group) and early conversion (CsA1 + SRL3) groups. As shown in Fig. 5 , the number of ED-1 positive cells, OPN mRNA and TIF score did not differ between CsA1 + W3 and CsA1 + SRL3 groups. Fig. 6 shows the number of TUNEL-positive cells and active caspase-3 expression in each experimental group. As expected, the number of TUNEL-positive cells and active caspase-3 expression did not differ significantly between CsA1 + W3 and CsA1 + SRL3 groups. Table 3 shows the effect of late conversion from CsA to SRL on the progression of chronic CsA nephropathy. Renal function was normalized after CsA withdrawal (CsA4 + W4 group), but late conversion of SRL (CsA4 + SRL4 group) caused deterioration of renal function as compared with the other groups (P < 0.05). ) and VH4 + SRL4 group (0.6 ± 0.1/0.5 mm 2 ) (P < 0.01 for CsA4 + W4 compared with other two groups). Switching CsA to SRL after 4 weeks increased the number of ED-1-positive cells to 32 ± 5/0.5 mm 2 (P < 0.01). Northern blot analysis showed a significantly greater OPN mRNA expression in the CsA4 + W4 group (151% ± 17%) compared with the VH4 + W4 (128% ± 28%) and VH4 + SRL4 groups (89% ± 35%) (P < 0.01 for the CsA4 + W4 compared with the two other groups). OPN mRNA expression was the highest in the late conversion from CsA to SRL (CsA4 + SRL4) group (691% ± 510%, P < 0.01 http://dx.doi.org/10.3346/jkms.2012.27.2.160 compared with the CsA4 + W4 group, Fig. 7B ).
Effect of early conversion on CsA-induced renal injury
Effect of late conversion on progression of chronic CsA nephropathy
The TIF score was higher in the CsA4 + W4 group (7.6 ± 1.1/ W4 group compared with the two other groups). The TIF score was highest in the late conversion from CsA to SRL group (16 ± 1/ 0.5 mm 2 ) than in the CsA4 + W4 group (7.6 ± 1.1/0.5 mm 2 , P < 0.01, Fig. 7C ). ) and VH4 + SRL4 group (4 ± 0.9/0.5 mm 2 , P < 0.01 for the CsA4 + W4 group compared with the two other groups). The number of apoptotic cells was even higher in the late conversion from CsA to SRL group (89 ± 3/0.5 mm 2 , P < 0.05 compared with the CsA4 + W4 group). Active caspase-3 protein levels were significantly higher in the CsA4 + W4 group (407% ± 70%) than the VH4 + W4 group (105% ± 5%) and the VH4 + SRL4 groups (115% ± 10%) (P < 0.01 for the CsA4 + W4 group compared with the two other groups). Active caspase-3 protein level was higher in the CsA4 + SRL4 group (1,029% ± 71%) compared with the CsA4 + W4 group (407% ± 70%, P < 0.05, Fig. 8B ).
DISCUSSION
Our study was performed to determine optimal timing of conversion from CsA to SRL in experimental model of chronic CsA nephropathy. The results of our study demonstrate clearly that early conversion to SRL attenuates the progression of CsA-induced renal injury, whereas late conversion to SRL does not provide beneficial effects. This finding suggests that the conversion from SRL to CsA should occur as early as possible, before the development of chronic renal injury by CsA.
SRL by itself does not cause serious renal injury, but combined SRL and CsA treatment has a synergic effect on the development of chronic CsA nephrotoxicity (4) (5) (6) (7) (8) . We first tested whether our experimental model of chronic CsA nephropathy produces similar results to those observed in clinical studies. SRL treatment alone did not induce significant nephrotoxicity but co-administration of CsA and SRL exacerbated CsA-induced renal injury. These results are consistent with the results of clinical studies, indicating that our model is suitable for studying SRL conversion.
To determine the optimal timing for conversion from CsA to SRL, we compared the effect of early and late conversion to SRL on CsA-induced renal injury. We chose day 7 as the time for early conversion and day 28 as the time for late conversion because CsA treatment for 4 weeks in our model induces renal dysfunction and chronic changes in kidney, whereas CsA treatment for 1 week causes minimal changes in renal function and histology (18, 19) . In our current study, early conversion from CsA to SRL did not cause further significant changes in renal functional or histology alterations compared with the early CsA withdrawal group. By contrast, late conversion from CsA to SRL did not improve renal function and histopathology (9, 10) . Actually, late conversion to SRL aggravated CsA-induced renal injury, as shown by a significant increase in interstitial inflammation and fibrosis, even after CsA withdrawal. This finding implies that the severity of CsA-induced renal injury is an important factor in the successful conversion to SRL.
A CONVERT study is to evaluate the effect of conversion from CsA to SRL at different time points after transplantation (6-120 months) (9) , and the effect of SRL conversion was evaluated in terms of graft function or degree of proteinuria. Our experimen- tal study is similar to CONVERT study in the point that SRL was directly converted from CsA at different stage (early and late) of CsA-induced renal injury. The results of CONVERT study showed clearly that SRL conversion is beneficial in patients with preserved graft function (baseline glomerular filtration rate more than 40 mL/min) but not in patients with a severely injured renal allograft. The results of our study were similar to those of CONVERT study. Early conversion of SRL before development of chronic change by CsA was effective in preventing CsA-induced renal injury but late conversion of SRL in established chronic CsA nephropathy failed to improve CsA-induced renal injury. This finding strengthens the rationale of CONVERT study that the effectiveness of SRL is dependent upon the status of graft function. We further evaluated the influence of SRL conversion at the molecular level. In experimental models of chronic CsA nephropathy, CsA-induced renal injury recruits macrophages, and this recruitment is mediated by several proinflammatory cytokines (13, 20) . OPN is proinflammatory mediator, and chronic CsA treatment increases OPN concentration in rat models (14) (15) (16) . The CsA-induced renal injury also upregulates the expression of active caspase-3 and leads to apoptotic cell death (17, 18 ). In our current study, early conversion to SRL did not change macrophage infiltration and OPN protein expression after CsA withdrawal. However late conversion to SRL potentiated macrophage infiltration and OPN expression even after CsA withdrawal. In addition, early but late conversion to SRL increased the active caspase-3 expression and the number of TUNEL-positive cells compared with the CsA withdrawal group. This finding confirms the idea that early conversion to SRL is beneficial for attenuating CsA-induced inflammation and apoptotic cell death.
We used an experimental model of chronic CsA nephropathy, but our model has some limitations when translated into clinical practice. First, CsA trough levels were much higher than those targeted in clinical practice. Second, our experimental model of chronic CsA nephropathy produces minimal proteinuria, and we could not observe influence of SRL on proteinuria. Third, a follow-up period for 8 weeks has been better for defining the relationship between CsA and SRL groups in experiment III. However, the study period could not be extended, because rats cannot survive beyond 4 weeks under high dose CsA (15 mg/kg) and low salt diet. Therefore, the results of our study should be translated cautiously to clinical practice.
In conclusion, the results of our study provide a theoretical basis for a CsA sparing strategy using SRL and that it is desirable to convert SRL from calcineurin inhibitors before development of chronic CsA nephrotoxicity.
